Skip to main content
OMDA
NASDAQ Industrial Applications And Services

Omada Health Reports Strong Q1 Growth, Reduced Losses; C-Suite Adopts Significant 10b5-1 Selling Plans

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$15.75
Mkt Cap
$873.275M
52W Low
$10.28
52W High
$28.4
52W Position info
53% above low
Off High info
45% below high
Rel. Volume info
2.5× avg
Market data snapshot near publication time

OMDA sits 53% above its 52-week low of $10.28 on elevated volume (2.5× avg).

Summary

Omada Health reported strong Q1 2026 financial results with significant revenue growth and reduced net losses, but also disclosed new Rule 10b5-1 selling plans by several C-suite executives and an ongoing material weakness in internal controls.


Key Events · Earnings and Guidance · OMDA

  • Strong Q1 2026 Financial Performance

    Total revenue increased by 42% to $78.0 million for the three months ended March 31, 2026, compared to $55.0 million in the prior-year period. Gross profit rose 53% to $48.7 million, with gross margin expanding by 4.4 percentage points to 62.4%.

  • Reduced Net Loss and Improved Operating Performance

    Net loss significantly decreased to $3.0 million for Q1 2026, down from $9.4 million in Q1 2025. Operating loss also improved to $4.8 million from $8.4 million in the comparable period.

  • C-Suite Adopts Significant 10b5-1 Selling Plans

    CEO Sean Duffy, CFO Steve Cook, President Wei-Li Shao, and CAO Craig Gracey adopted Rule 10b5-1 trading plans in March 2026 for the sale of common stock and shares received from RSU vesting. The known shares to be sold total over 1 million, representing a substantial amount.

  • Ongoing Material Weakness in Internal Controls

    The company continues to report a material weakness in internal control over financial reporting related to inadequate formalized processes and control activities, a known issue from the 2025 10-K, with remediation efforts underway.


Analysis · OMDA · Industrial Applications And Services

Omada Health's Q1 2026 results confirm robust performance, with revenue surging 42% year-over-year and net losses significantly narrowing. This positive financial update follows the preliminary results reported in the recent 8-K filing. However, the filing also discloses that multiple C-suite executives, including the CEO and CFO, adopted Rule 10b5-1 trading plans in March 2026 for the sale of a substantial number of shares, representing a notable amount relative to the company's market capitalization. While these are pre-planned sales, they introduce a negative sentiment regarding insider conviction. The company also continues to report a material weakness in internal controls over financial reporting, a known issue from its prior 10-K, with ongoing remediation efforts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OMDA was trading at $15.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $873.3M. The 52-week trading range was $10.28 to $28.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OMDA - Latest Insights

OMDA
Nov 05, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $19.99
Real-time Price: $11.81 info
Change: -$8.18 (-41%) info
Market Cap: $736.388M info
OMDA
Nov 05, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.95
Real-time Price: $11.81 info
Change: -$7.14 (-38%) info
Market Cap: $736.388M info
OMDA
Sep 10, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.84
Real-time Price: $11.81 info
Change: -$10.03 (-46%) info
Market Cap: $736.388M info
OMDA
Sep 09, 2026, 9:01 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.18
Real-time Price: $11.81 info
Change: -$10.37 (-47%) info
Market Cap: $736.388M info
OMDA
Aug 07, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.67
Real-time Price: $11.81 info
Change: -$11.86 (-50%) info
Market Cap: $736.388M info